ストックスクリーナーアプリを入手
0.69
8.09%
0.0524
Context Therapeutics Inc (CNTX) 最新ニュース
Context Therapeutics Joins Russell 2000, Russell 3000 Indexes - Moomoo
Context Therapeutics stock rises on Russell index inclusion By Investing.com - Investing.com Nigeria
Context Therapeutics Added to Russell 2000® and Russell 3000® Indexes - GlobeNewswire
Context Therapeutics joins Russell 2000 and 3000 indexes - Stock Titan
Diluted net income available to common stockholders of Context Therapeutics, Inc. – DUS:6K9 - TradingView
Maxim Says Context Therapeutics (CNTX)’s Share Pullback Is an Overreaction; Remains Bullish - Yahoo Finance
CNTX Stock Price, Quote & Chart - ChartMill
Context Therapeutics Inc.(NasdaqCM:CNTX) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Context Therapeutics Inc.(NasdaqCM: CNTX) added to Russell 2500 Growth Benchmark - marketscreener.com
Context Therapeutics Inc.(NasdaqCM: CNTX) added to Russell 2000 Index - marketscreener.com
Context Therapeutics Inc.(NasdaqCM:CNTX) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Context Therapeutics Inc.(NasdaqCM: CNTX) added to Russell 2000 Growth Benchmark - marketscreener.com
Context Therapeutics Inc.(NasdaqCM: CNTX) added to Russell 3000E Growth Benchmark - marketscreener.com
Enterprise value to EBITDA forward of Context Therapeutics, Inc. – MUN:6K9 - TradingView
Enterprise value to revenue forward of Context Therapeutics, Inc. – MUN:6K9 - TradingView
Context Therapeutics Inc.(NasdaqCM: CNTX) added to Russell 3000 Growth Benchmark - marketscreener.com
Context Therapeutics Shareholders Approve Stock Increase and Directors - The Globe and Mail
Price to book forward of Context Therapeutics Inc. – NASDAQ:CNTX - TradingView
Context Therapeutics (CNTX) director receives grant of 45,000 stock options at $0.576 - Stock Titan
Context Therapeutics (CNTX) director awarded 45,000 stock options at $0.576 - Stock Titan
Context Therapeutics (CNTX) director Linda West awarded 45K stock options - Stock Titan
Director at Context Therapeutics (CNTX) receives 45,000 stock options award - Stock Titan
Director Philip Kantoff receives 45,000 CNTX stock options at $0.576 exercise price - Stock Titan
Context Therapeutics (NASDAQ: CNTX) wins approval to lift share authorization to 300M - Stock Titan
Context Therapeutics, Inc. Actuals & Estimates (NASDAQ:CNTX) - TradingView
Price to sales forward of Context Therapeutics Inc. – NASDAQ:CNTX - TradingView
Price to sales forward of Context Therapeutics, Inc. – GETTEX:6K9 - TradingView
CNTX Forecast — Price Target — Prediction for 2027 - TradingView
Price to book forward of Context Therapeutics, Inc. – GETTEX:6K9 - TradingView
Price to earnings forward of Context Therapeutics Inc. – NASDAQ:CNTX - TradingView
Enterprise value to EBIT forward of Context Therapeutics Inc. – NASDAQ:CNTX - TradingView
Context Therapeutics (CNTX) Rallies 5% as Biotech Stock Tests Key ResistanceMFI Overbought - dars.gov.et
Context Therapeutics Inc (CNTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Context Therapeutics Inc (CNTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Context Therapeutics Inc (CNTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Context Therapeutics Inc (CNTX) Institutional Confidence - TradingKey
Context Therapeutics Inc (CNTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Context Therapeutics Inc (CNTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Context Therapeutics Inc (CNTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Context Therapeutics Inc (CNTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Context Therapeutics Inc (CNTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Maxim Group Maintains Context Therapeutics(CNTX.US) With Buy Rating, Maintains Target Price $4 - Moomoo
CNTX Maintained by Maxim Group -- Price Target Lowered to $4.00 - GuruFocus
Analysts Offer Insights on Healthcare Companies: Dyadic International (DYAI) and Context Therapeutics (CNTX) - The Globe and Mail
Context Therapeutics Reports 29% Response Rate for CTIM-76 in Platinum-Resistant Ovarian Cancer Phase 1 Trial - BioPharm International
Revenue per share of Context Therapeutics, Inc. – DUS:6K9 - TradingView
EBIT per share of Context Therapeutics, Inc. – DUS:6K9 - TradingView
Context Therapeutics price target lowered to $4 from $8 at Maxim - TipRanks
Basic earnings per share (basic EPS) of Context Therapeutics, Inc. – DUS:6K9 - TradingView
Context Therapeutics, Inc. Balance Sheet – DUS:6K9 - TradingView
Context Therapeutics Highlights Positive CTIM-76 Phase 1 Data - The Globe and Mail
Cost of goods sold of Context Therapeutics, Inc. – DUS:6K9 - TradingView
CNTX Hits Worst Day In History After Ovarian Cancer Trial Data — But Analysts See Buying Opportunity In Dip - Asianet Newsable
Small biotech Context Therapeutics reports 29% response rate in ovarian cancer study - MSN
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Context Therapeutics Announces Positive Inter - Moomoo
Context Therapeutics rises on interim Phase 1 ovarian cancer data - grafa.com
Context Therapeutics Reports Encouraging Phase 1 Results for CTIM-76 T Cell Engager in Platinum-Resistant Ovarian Cancer – Minichart - Minichart
Context Therapeutics to Proceed With Next Development Phase of CTIM-76 in Ovarian Cancer - Moomoo
CNTX: CTIM-76 achieved a 29% response rate and low-grade CRS in heavily pretreated PROC patients - TradingView
Context reports positive interim Phase 1 CTIM-76 data with 29% ORR in PROC, low CRS - TradingView
Context Therapeutics (NASDAQ: CNTX) shows early CTIM-76 activity in platinum-resistant ovarian cancer - Stock Titan
CNTX: CTIM-76 shows 29% response and strong safety in late-line platinum-resistant ovarian cancer - TradingView
Context Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase 1 Clinical Trial for CTIM-76 - The Manila Times
Context Therapeutics Announces Positive Interim Efficacy And Safety Results From Ongoing Phase 1 Clinical Trial For CTIM-76 - TradingView
Context Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase ... - Caledonian Record
Context Therapeutics Announces Positive Interim Efficacy - GlobeNewswire
Context Therapeutics Grants New-Hire Equity Award Under Nasdaq Rule - MyChesCo
1.26%
3.59%
大文字化:
|
ボリューム (24 時間):